AstraZeneca
AstraZeneca says its trial drug for thyroid cancer granted US FDA orphan drug designation
May 12, 2016Research and Development, Sales and Marketing AstraZeneca, Orphan Drug Designation, US FDA, drug trial, regulation
AstraZeneca (LSE: AZN) on Thursday said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation its trial …
Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
Allergan launches Crestor generic in the US
May 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
AstraZeneca Q1 earnings down 12%; maintains FY view
April 29, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Q!, earnings, outlook, profits, q, results
UK drugmaker AstraZeneca (LSE: AZN) on Friday reported a 12% drop in first-quarter earnings and said it plans to streamline …
AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals
April 27, 2016Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales
AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …
AstraZeneca’s COPD therapy gets US FDA approval
April 26, 2016Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval
UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …
AstraZeneca to sequence genomes to develop new drugs
April 22, 2016Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute
AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials
April 13, 2016Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …
Clinical studies point to consistent efficacy in AstraZeneca’s treatment for drug-resistance bacteria
April 12, 2016Manufacturing and Production, Research and Development AstraZeneca, avibactam, ceftazidime, gram resistant
AstraZeneca has presented results from a series of trials which show the consistent efficacy of investigational antibiotic, ceftazidime-avibactam (CAZ-AVI) in …
FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge
April 11, 2016AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib
Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …
AstraZeneca and Eli Lilly to enter Phase III on Alzheimer’s clinical trials
April 8, 2016Medical Communications AZD3293, Alzheimer's, Alzheimers, AstraZeneca, amaranth, clinical trial, lilly, phase III
AstraZeneca and Eli Lilly have announced the continuation of their clinical trial for people with early Alzheimer’s disease into Phase …
Japanese approval for AZ lung cancer drug
March 29, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Tagrisso, lung cancer
AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the treatment of a specific form of clung cancer. Japanese regulator, …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
